MATISSE(孕产妇免疫安全性与有效性研究)二价呼吸道合胞病毒预融合F蛋白疫苗孕产妇试验中的早产频率及相关结局
MATISSE是一项全球3期随机双盲试验,7,386名孕妇接受RSVpreF疫苗或安慰剂。总体分析中两组特殊不良事件(包括早产、低出生体重、新生儿住院)无临床显著增加,但非高收入国家亚组早产风险升高,需进一步研究。
要点
- 总体早产率RSVpreF组5.7% vs 安慰剂组4.7%(RR 1.20,95%CI 0.98-1.46)。
- 高收入国家两组早产率均为5.0%;非高收入国家RSVpreF组7.0% vs 安慰剂组4.0%。
- 南非早产率RSVpreF组8.3% vs 安慰剂组4.0%(RR 2.06,95%CI 1.21-3.51)。
核心结论
- 总体分析中,孕期接种RSVpreF疫苗未观察到特殊不良事件(包括早产、低出生体重或新生儿住院)的临床显著增加。
- 非高收入国家亚组分析中观察到早产风险升高,需进一步研究以明确早产危险因素,尤其旨在减少地理区域间差异。
研究设计与样本
- MATISSE为全球、3期、随机、双盲试验,孕妇接受单次注射RSVpreF或安慰剂。
- 共7,386名孕妇接受RSVpreF(n=3,698)或安慰剂(n=3,688),7,305名新生儿和婴儿纳入分析。
- 特殊不良事件(包括早产[孕周小于37周]和低出生体重[2,500 g或以下])收集至分娩后6个月(孕妇参与者)及从出生至12或24月龄(儿童参与者)。
- 研究由辉瑞资助,临床试验注册号NCT04424316。
主要发现
- 两组大多数儿童为足月产(超过93%)且出生体重正常(95%或更高)。
- 早产率RSVpreF组5.7% vs 安慰剂组4.7%(RR 1.20,95%CI 0.98-1.46),多数为晚期早产。
- 研究期间发生22例新生儿或婴儿死亡(RSVpreF组n=8,安慰剂组n=14)。
- 按收入地区分层,高收入国家RSVpreF组和安慰剂组早产率均为5.0%。
- 非高收入国家早产率RSVpreF组7.0% vs 安慰剂组4.0%;南非RSVpreF组8.3% vs 安慰剂组4.0%(RR 2.06,95%CI 1.21-3.51)。
局限性
- 需进一步研究以更好地明确早产危险因素,尤其旨在减少地理区域间差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe preterm birth frequency and newborn and infant outcomes overall and among preterm children in the MATISSE (Maternal Immunization Study for Safety and Efficacy) trial of maternal vaccination with bivalent respiratory syncytial virus (RSV) prefusion F protein-based vaccine (RSVpreF) to protect infants against severe RSV-associated illness. METHODS: MATISSE was a global, phase 3, randomized, double-blind trial. Pregnant individuals received single injections of RSVpreF or placebo. Adverse events of special interest, including preterm birth (gestational age less than 37 weeks) and low birth weight (2,500 g or less), were collected through 6 months after delivery (pregnant participants) and from birth through age 12 or 24 months (pediatric participants). RESULTS: Overall, 7,386 pregnant participants received RSVpreF (n=3,698) or placebo (n=3,688); 7,305 newborns and infants were included in the analysis. Most children in both groups were born full term (more than 93%) with normal birth weight (95% or higher). Newborn and infant outcomes, including rates of low birth weight and neonatal hospitalization, were favorable and comparable between groups. Preterm birth rates were 5.7% in the RSVpreF arm and 4.7% in the placebo arm (relative risk [RR] 1.20, 95% CI, 0.98-1.46); most were late preterm. Newborn and infant outcomes, including rates of low birth weight and neonatal hospitalization, were comparable between groups. Twenty-two newborn or infant deaths occurred during the study (RSVpreF n=8, placebo n=14). When stratified by income region, preterm birth rates in RSVpreF and placebo recipients were both 5.0% in high-income countries. Rates in non-high-income countries were 7.0% and 4.0% in the RSVpreF and placebo groups, respectively, and 8.3% and 4.0% in South Africa (RR 2.06, 95% CI, 1.21-3.51). CONCLUSION: In this study of maternal RSVpreF vaccination, no clinically significant increase in adverse events of special interest, including preterm birth, low birth weight, or neonatal hospitalization, was observed among pregnant people in the overall analysis. In subgroup analysis of non-high-income countries, an elevated risk of preterm birth was observed. More research is needed to better ascertain preterm delivery risk factors, particularly aimed at minimizing disparities among geographic regions. FUNDING SOURCE: This study was sponsored by Pfizer. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT04424316.
引用
- Madhi SA, Kampmann B, Simões EAF, et al. Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine. Obstet Gynecol. 2025. PMID: 39746206. doi:10.1097/AOG.0000000000005817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。